What is Better than Semaglutide for Weight Loss?

Last reviewed: June 5, 2026

Last updated: June 5, 2026

Written by: Jay Hastings, CEO of PlexusDx

Jay Hastings is the CEO of PlexusDx, a precision health company focused on genetic testing, blood biomarker insights, and personalized wellness recommendations. He has more than 20 years of experience across healthcare innovation, genomics, laboratory operations, healthcare investing, and strategic finance.

Medically reviewed by: Jayden Lee, PharmD, EMBA

Jayden Lee, PharmD, EMBA, is the PlexusDx Medical Science Liaison with a PharmD and MBA specializing in pharmacogenomics and clinical product development, with a proven ability to bridge the gap between genomic research and practical patient outcomes. Dr. Lee has more than 10 years of professional experience in clinical pharmacy, academia, and research.

This article is part of the PlexusDx Education Hub — science-backed guidance on GLP-1 medications, metabolic health, and precision weight management.

Semaglutide reduces appetite through GLP-1 receptor activation, producing average weight loss of 15% in clinical trials. However, individual response varies significantly based on genetics, lifestyle, and peptide-pathway sensitivity. PlexusDx offers multiple evidence-based alternatives that may outperform semaglutide for your specific metabolism.

Tirzepatide: The Dual-Hormone GLP-1 Alternative

Tirzepatide activates both GLP-1 and GIP receptors, stimulating dual-hormone pathways that regulate appetite and blood sugar simultaneously. Clinical trials show tirzepatide produces 22% average weight loss over 68 weeks—approximately 7% greater than semaglutide monotherapy. The dual mechanism targets two independent satiety signals, which may explain superior outcomes in patients with genetic variants affecting GLP-1 sensitivity.

PlexusDx Compounded Tirzepatide Injection is $289/mo month-to-month (or $249/mo on the 6-month plan) across all commitment tiers, with your dose adjusting upward as tolerated while pricing remains flat. Oral tirzepatide is available at $349/mo (or $279/mo on the 6-month plan) for patients preferring tablet formulations. Licensed 503A compounding pharmacies ensure pharmaceutical-grade purity and consistent potency across all batches.

GLP-Squared: Combining Semaglutide and Tirzepatide

GLP-Squared is a precision dual-compound injection combining semaglutide and tirzepatide in a single formulation, allowing titration of both peptides simultaneously. This approach maximizes GLP-1 pathway activation while adding GIP-receptor engagement without separate injections. Patients with genetic resistance to single-agent therapy often experience breakthrough weight loss acceleration when dual compounds activate complementary satiety mechanisms.

GLP-Squared Injection begins at $289/mo (or $249/mo on the 3-month plan), while the oral version starts at $389/month, both maintaining flat pricing regardless of dose escalation. The dual-compound strategy is particularly beneficial for patients whose Precision Peptide Genetic Test reveals reduced sensitivity to GLP1R rs6923761 variants, suggesting lower natural GLP-1 responsiveness.

Microdose GLP-1 Protocol: Gentler Results with High Compliance

Microdose GLP-1 protocols use subclinical doses of semaglutide or tirzepatide to suppress appetite without gastrointestinal side effects that commonly cause discontinuation. Patients on microdose regimens report sustained 10–14% weight loss with nausea rates below 5%, compared to 30% nausea rates in standard-dose cohorts. Lower side-effect burden dramatically improves medication adherence, often translating to better long-term outcomes despite smaller initial dose magnitudes.

PlexusDx Microdose GLP-1 Protocol is available at $129/month flat, making it the most affordable entry point to peptide therapy. This option suits patients prioritizing tolerability over rapid weight loss, those with comorbid nausea or gastric sensitivity, and individuals beginning their weight-loss journey. Microdose protocols can be escalated to standard tiers if tolerance and motivation improve over time.

Genetic Testing Reveals Your Best GLP-1 Match

Response to semaglutide and tirzepatide depends partly on genetic variants in GLP-1 and GIP receptor genes, as well as metabolic pathways governing appetite control. PlexusDx Precision Peptide Genetic Test analyzes 14 metabolic pathways, 49 peptides, and 150+ genetic insights including key variants: GLP1R rs6923761 (GLP-1 sensitivity), GIPR rs1800437 (GIP-receptor function), FTO rs9939609 (appetite regulation), and MC4R rs17782313 (satiety signaling). Patients with unfavorable GLP1R variants often require higher doses or combination therapy to achieve semaglutide-equivalent results.

The PlexusDx Precision Peptide Genetic Test ($298) analyzes GIPR, FTO, and MC4R — variants that relate to GLP-1 and related signaling pathways. It does not predict your response to semaglutide or determine your dose; it offers pathway-level context for a conversation with your provider. Genetics is a guide, not a guarantee.

Comparing Cost and Accessibility Across Options

PlexusDx serves all 50 states without insurance requirements, membership fees, or prior authorization delays. Compounded medications from licensed 503A pharmacies are HSA and FSA eligible, reducing out-of-pocket costs for eligible patients. Pricing remains flat regardless of dose tier—your dose may go up, but your monthly price stays the same, eliminating surprise cost increases as you optimize therapy.

Semaglutide Injection begins at $189/mo (or $149/mo on the 6-month plan), Tirzepatide at $289/month, and Microdose GLP-1 at $129/month, with all options shipped directly to your home. Oral formulations cost slightly more (Oral Semaglutide $289/month, Oral Tirzepatide $349/month) due to bioavailability challenges but offer needle-free convenience. Dual-compound options start at $289/month for injection and $369/month for oral, providing maximum flexibility across budget and preference.

How Your Genetics Relate to GLP-1 Pathways

Not everyone responds to GLP-1 medications the same way. Genetic variants — including GIPR rs1800437, FTO rs9939609, and MC4R rs17782313 — relate to the biological pathways these medications act on. These are pathway-level associations only and do not predict how much weight you will lose or how you will respond to any specific medication. PlexusDx maps 14 pathways, 49 peptides, and 150+ genetic insights so you and your provider can see how your genes relate to these pathways. It does not recommend, prescribe, or determine which medication, dose, or peptide is right for you. The PlexusDx Precision Peptide Genetic Test ($298) gives you and your provider pathway-level genetic context to support a more personalized conversation. Genetics is a guide, not a guarantee.

Access Personalized GLP-1 Care Through PlexusDx

PlexusDx offers seven prescription GLP-1 protocols to all 50 states — no membership, no insurance required, async intake or live consult. The Semaglutide Injection is $189/mo month-to-month, or from $149/mo on the 6-month plan. Medications are dispensed from licensed 503A compounding pharmacies following strict quality and safety standards. Add a Precision Peptide Genetic Test for $298 to personalize your protocol from day one.

Frequently Asked Questions

Is tirzepatide always better than semaglutide for weight loss?

Tirzepatide produces approximately 7% greater average weight loss in clinical trials, but individual response varies. Some patients respond excellently to semaglutide alone, while others achieve breakthrough results only when tirzepatide or dual compounds activate their GIP pathway.

What clinical evidence supports dual-compound GLP-1 therapy?

The SURMOUNT trials demonstrate tirzepatide superiority over semaglutide, and emerging data shows that combining both peptides can further amplify weight loss and metabolic improvement in patients with genetic resistance to single agents. Dual activation of GLP-1 and GIP receptors engages independent appetite-suppression pathways simultaneously.

Can I switch from semaglutide to tirzepatide if I'm not losing weight?

Yes. PlexusDx clinicians regularly transition patients between medication tiers based on progress and tolerance. Many patients who plateau on semaglutide experience renewed weight loss acceleration when switching to tirzepatide or GLP-Squared, especially if genetic testing reveals GIP-pathway variants favoring dual-compound therapy.

Will microdose GLP-1 help me lose weight if standard doses cause nausea?

Absolutely. Microdose protocols maintain appetite suppression at 10–14% weight loss while reducing nausea to below 5%, making them ideal for patients whose side effects prevented adherence to standard semaglutide. PlexusDx Microdose GLP-1 Protocol at $129/month offers a tolerable entry point that can be escalated as your body adapts.

How does genetic testing help me choose between semaglutide and tirzepatide?

No — the Precision Peptide Genetic Test does not predict your response to semaglutide or any specific medication. It analyzes pathway-level variants (GIPR, FTO, and MC4R) that relate to the biology involved, offering context for a conversation with your provider rather than a prediction.

Related Reading

• Semaglutide For Weight Loss 2
• Semaglutide Tablets For Weight Loss
• Semaglutide Pills For Weight Loss
• Oral Semaglutide Weight Loss

Pricing and availability current as of June 2026. Compounded GLP-1 medications are not FDA-approved drug products; they are prepared by licensed compounding pharmacies under federal compounding regulations. Compounded semaglutide and tirzepatide are not the same as Wegovy, Ozempic, Zepbound, or Mounjaro. This article is for informational purposes only and does not constitute medical advice. Consult a licensed healthcare provider before starting, stopping, or changing any medication.

Return to the PlexusDx Education Hub for more evidence-based resources on GLP-1 therapy, metabolic health, and personalized weight management.

Medical and Editorial Standards

Medical review process: This article was reviewed for medical accuracy, scientific clarity, evidence alignment, and appropriate discussion of genetics, medications, supplements, biomarkers, and health-related claims.

Sources and evidence: PlexusDx educational content is developed using peer-reviewed research, clinical literature, reputable medical references, and, where applicable, public health or regulatory guidance.

Commercial transparency: PlexusDx offers genetic testing, blood biomarker testing, personalized supplement recommendations, and related precision wellness services. Product mentions are intended to help readers understand available options and should not be interpreted as medical advice.

Important disclaimer: PlexusDx educational content is for informational purposes only and should not be used as a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making decisions about medications, supplements, genetic testing, lab testing, or health-related care.